Il Topiramato nella terapia di profilssi delle micrania: Uno studio pilota

Translated title of the contribution: Topiramate in migraine prophilaxis: A pilot study

D. Di Trapani, D. Mei, C. Marra, S. Mazza, A. Capuano

Research output: Contribution to journalArticle

Abstract

Topiramate is an antiepileptic drug of new generation that modulates voltage-dependent sodium conductance, potentiates gamma-aminobutyric acid-evoked currents, and blocks the kainate/AMP A (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) subtype of the glutamate receptor. We report the results of a three-month open study on the effects of topiramate in the prophylaxis of patients with migraine meeting the IHS criteria. We treated 20 patients suffering from migraine with or without aura. Patients treated their attack at home using symptomatic drugs and clinical assessment was recorded on a diary. After a washout of 8 week from any other prophylactic treatment, all patients were treated with 100 mg/day of topiramate; this is our therapeutic plan: 50 mg/day from 1(st) to 7(th) day and 100 mg/day from 8(th) day. No patients withdrew, topiramate was well tolerated; adverse events (vertigo, ataxia, paraesthesia, speech disorders) generally were transient and mild to moderate in severity. At the end of treatment, in such case, we reported a significative reduction of frequency and intensity of migraine in all patients treated with topiramate. Our observations indicate that topiramate is well tolerated by patients and that reduces headache frequency and use of symptomatic drugs in both groups.

Original languageItalian
Pages (from-to)152-159
Number of pages8
JournalActa Medica Romana
Volume38
Issue number1-2
Publication statusPublished - 2000

Fingerprint

Migraine Disorders
Migraine without Aura
Speech Disorders
Migraine with Aura
Paresthesia
Kainic Acid
Vertigo
Glutamate Receptors
Ataxia
Adenosine Monophosphate
topiramate
Pharmaceutical Preparations
Anticonvulsants
gamma-Aminobutyric Acid
Headache
Therapeutics
Sodium

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Di Trapani, D., Mei, D., Marra, C., Mazza, S., & Capuano, A. (2000). Il Topiramato nella terapia di profilssi delle micrania: Uno studio pilota. Acta Medica Romana, 38(1-2), 152-159.

Il Topiramato nella terapia di profilssi delle micrania : Uno studio pilota. / Di Trapani, D.; Mei, D.; Marra, C.; Mazza, S.; Capuano, A.

In: Acta Medica Romana, Vol. 38, No. 1-2, 2000, p. 152-159.

Research output: Contribution to journalArticle

Di Trapani, D, Mei, D, Marra, C, Mazza, S & Capuano, A 2000, 'Il Topiramato nella terapia di profilssi delle micrania: Uno studio pilota', Acta Medica Romana, vol. 38, no. 1-2, pp. 152-159.
Di Trapani, D. ; Mei, D. ; Marra, C. ; Mazza, S. ; Capuano, A. / Il Topiramato nella terapia di profilssi delle micrania : Uno studio pilota. In: Acta Medica Romana. 2000 ; Vol. 38, No. 1-2. pp. 152-159.
@article{12e3667a074545bca6ab8e8c1402ca73,
title = "Il Topiramato nella terapia di profilssi delle micrania: Uno studio pilota",
abstract = "Topiramate is an antiepileptic drug of new generation that modulates voltage-dependent sodium conductance, potentiates gamma-aminobutyric acid-evoked currents, and blocks the kainate/AMP A (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) subtype of the glutamate receptor. We report the results of a three-month open study on the effects of topiramate in the prophylaxis of patients with migraine meeting the IHS criteria. We treated 20 patients suffering from migraine with or without aura. Patients treated their attack at home using symptomatic drugs and clinical assessment was recorded on a diary. After a washout of 8 week from any other prophylactic treatment, all patients were treated with 100 mg/day of topiramate; this is our therapeutic plan: 50 mg/day from 1(st) to 7(th) day and 100 mg/day from 8(th) day. No patients withdrew, topiramate was well tolerated; adverse events (vertigo, ataxia, paraesthesia, speech disorders) generally were transient and mild to moderate in severity. At the end of treatment, in such case, we reported a significative reduction of frequency and intensity of migraine in all patients treated with topiramate. Our observations indicate that topiramate is well tolerated by patients and that reduces headache frequency and use of symptomatic drugs in both groups.",
author = "{Di Trapani}, D. and D. Mei and C. Marra and S. Mazza and A. Capuano",
year = "2000",
language = "Italian",
volume = "38",
pages = "152--159",
journal = "Acta Medica Romana",
issn = "0001-6098",
publisher = "Vita e Pensiero",
number = "1-2",

}

TY - JOUR

T1 - Il Topiramato nella terapia di profilssi delle micrania

T2 - Uno studio pilota

AU - Di Trapani, D.

AU - Mei, D.

AU - Marra, C.

AU - Mazza, S.

AU - Capuano, A.

PY - 2000

Y1 - 2000

N2 - Topiramate is an antiepileptic drug of new generation that modulates voltage-dependent sodium conductance, potentiates gamma-aminobutyric acid-evoked currents, and blocks the kainate/AMP A (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) subtype of the glutamate receptor. We report the results of a three-month open study on the effects of topiramate in the prophylaxis of patients with migraine meeting the IHS criteria. We treated 20 patients suffering from migraine with or without aura. Patients treated their attack at home using symptomatic drugs and clinical assessment was recorded on a diary. After a washout of 8 week from any other prophylactic treatment, all patients were treated with 100 mg/day of topiramate; this is our therapeutic plan: 50 mg/day from 1(st) to 7(th) day and 100 mg/day from 8(th) day. No patients withdrew, topiramate was well tolerated; adverse events (vertigo, ataxia, paraesthesia, speech disorders) generally were transient and mild to moderate in severity. At the end of treatment, in such case, we reported a significative reduction of frequency and intensity of migraine in all patients treated with topiramate. Our observations indicate that topiramate is well tolerated by patients and that reduces headache frequency and use of symptomatic drugs in both groups.

AB - Topiramate is an antiepileptic drug of new generation that modulates voltage-dependent sodium conductance, potentiates gamma-aminobutyric acid-evoked currents, and blocks the kainate/AMP A (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) subtype of the glutamate receptor. We report the results of a three-month open study on the effects of topiramate in the prophylaxis of patients with migraine meeting the IHS criteria. We treated 20 patients suffering from migraine with or without aura. Patients treated their attack at home using symptomatic drugs and clinical assessment was recorded on a diary. After a washout of 8 week from any other prophylactic treatment, all patients were treated with 100 mg/day of topiramate; this is our therapeutic plan: 50 mg/day from 1(st) to 7(th) day and 100 mg/day from 8(th) day. No patients withdrew, topiramate was well tolerated; adverse events (vertigo, ataxia, paraesthesia, speech disorders) generally were transient and mild to moderate in severity. At the end of treatment, in such case, we reported a significative reduction of frequency and intensity of migraine in all patients treated with topiramate. Our observations indicate that topiramate is well tolerated by patients and that reduces headache frequency and use of symptomatic drugs in both groups.

UR - http://www.scopus.com/inward/record.url?scp=0033677123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033677123&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0033677123

VL - 38

SP - 152

EP - 159

JO - Acta Medica Romana

JF - Acta Medica Romana

SN - 0001-6098

IS - 1-2

ER -